VCANBIO(600645)2024-10-29 08:37Financial Performance - Total revenue for Q3 2024 was CNY 403,616,982.90, a decrease of 0.17% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was CNY 48,327,768.55, down 3.03% year-on-year[2]. - Basic earnings per share for Q3 2024 was CNY 0.11, an increase of 10.00% compared to the same period last year[4]. - Total operating revenue for the first three quarters of 2024 reached CNY 1,205,902,310.99, slightly up from CNY 1,202,361,554.62 in the same period of 2023, reflecting a growth of approximately 0.2%[14]. - Operating profit for the first three quarters of 2024 was CNY 177,011,409.35, compared to CNY 172,285,093.77 in 2023, showing an increase of approximately 2.1%[16]. - Net profit for the first three quarters of 2024 amounted to CNY 176,618,190.32, up from CNY 173,711,071.15 in the previous year, representing a growth of around 1.6%[16]. - The net profit for Q3 2024 is approximately ¥132.51 million, compared to ¥129.36 million in Q3 2023, reflecting a slight increase[17]. - The net profit attributable to shareholders of the parent company is approximately ¥133.51 million, up from ¥132.51 million year-over-year[17]. - The total comprehensive income for Q3 2024 is approximately ¥124.29 million, down from ¥143.90 million in Q3 2023[17]. - Basic and diluted earnings per share for Q3 2024 are both ¥0.29, compared to ¥0.28 in Q3 2023[17]. Assets and Liabilities - Total assets at the end of Q3 2024 amounted to CNY 5,280,483,632.69, a decrease of 2.42% from the end of the previous year[4]. - The total assets decreased to CNY 5,280,483,632.69 from CNY 5,411,355,244.74, reflecting a decline of about 2.4%[13]. - The company's total liabilities amounted to CNY 1,600,647,096.73, slightly down from CNY 1,612,743,955.98, a reduction of about 0.7%[13]. - Non-current liabilities totaled CNY 118,803,383.98, down from CNY 131,006,703.81, indicating a decrease of approximately 9.3%[13]. - Shareholders' equity attributable to the parent company was CNY 3,616,459,711.87, down 1.84% from the end of the previous year[4]. - The equity attributable to shareholders decreased to CNY 3,616,459,711.87 from CNY 3,684,062,269.13, reflecting a decline of approximately 1.8%[13]. Cash Flow - Cash flow from operating activities for the year-to-date was CNY 177,349,411.66, a decrease of 4.45% year-on-year[2]. - Cash inflow from operating activities totaled approximately ¥1.24 billion for the first nine months of 2024, compared to ¥1.26 billion in 2023[18]. - Cash outflow from operating activities for the first nine months of 2024 is approximately ¥1.06 billion, down from ¥1.08 billion in 2023[18]. - The net cash flow from investing activities for the first nine months of 2024 is approximately -¥53.08 million, compared to -¥61.96 million in the same period of 2023[19]. - The net cash flow from financing activities for the first nine months of 2024 is approximately -¥264.76 million, compared to -¥9.86 million in 2023[19]. - The cash and cash equivalents at the end of Q3 2024 amount to approximately ¥1.44 billion, down from ¥1.51 billion at the end of Q3 2023[19]. - As of September 30, 2024, the company's cash and cash equivalents amounted to RMB 1,438,428,600.64, a decrease from RMB 1,581,245,197.15 as of December 31, 2023, reflecting a decline of approximately 9.0%[11]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 35,801[7]. - The largest shareholder, Tianjin Deyuan Health Management Co., Ltd., holds 12.14% of the shares[7]. - The company completed a share buyback of 12,052,740 shares, representing 2.58% of the total share capital, with a total expenditure of between RMB 100 million and RMB 200 million[10]. - The company plans to use RMB 50 million to RMB 100 million for share repurchase to maintain company value and shareholder rights[10]. Inventory and Receivables - Accounts receivable increased to RMB 638,842,642.46 from RMB 567,097,330.17, representing a growth of about 12.6%[11]. - The company's inventory stood at RMB 264,987,040.72, up from RMB 247,895,611.07, indicating an increase of approximately 6.0%[11]. - The total current assets decreased to RMB 2,454,434,396.91 from RMB 2,508,499,909.86, a decline of about 2.2%[11]. - The company reported an increase in long-term equity investments to RMB 210,900,102.12 from RMB 216,938,901.85, a decrease of about 2.0%[11]. - The company’s other equity instrument investments rose to RMB 456,862,467.76 from RMB 454,328,054.74, reflecting a slight increase of approximately 1.1%[11]. - The company’s receivables financing decreased to RMB 1,110,743.50 from RMB 4,072,294.96, a significant drop of about 72.7%[11]. Research and Development - Research and development expenses increased to CNY 135,327,118.77 from CNY 117,503,490.16, marking a rise of approximately 15.1%[16]. Non-recurring Gains and Losses - Non-recurring gains and losses included government subsidies of CNY 2,510,716.75 for the current period[5].